An engineered peptide could kill an entire category of highly resistant bugs that are behind potentially lethal infections such as pneumonia and sepsis. The synthetic drugs acts by shredding and dissolving their double-layered membranes, believed to shield these gram negative bugs from antibiotics, which include E. coli and those that cause gonorrhea, typhoid fever, cholera, syphilis, plague, and Lyme disease. "The antibiotic pipeline against multidrug-resistant Gram-negative problem pathogens is a major unmet need in contemporary medicine; as such, our new antimicrobial agent holds immediate promise," said study co-author Wadih Arap, professor at the University of Texas MD Anderson's Cancer Centre, the journal Proceedings of the National Academy of Science reports. Arap, Renata Pasqualini, also study co-author and professor at Texas Cancer Centre, and colleagues have previously constructed peptide combinations that are in development against cancer and white fat cells, according to a Texas statement. "The prototype introduced here as an antibiotic candidate has a unique mechanism of action and translational applications readily identified," Pasqualini said. The spiral peptide called KLAKLAKKLAKLAK acts against bacteria by puncturing their lipid bilayer membranes and has only low toxicity toward mammalian cells.
GMT 14:01 2018 Thursday ,30 August
Expat with rare heart disorder gets life-saving surgeryGMT 00:18 2018 Tuesday ,23 January
Boy with 10-pound tumour on face diesGMT 21:23 2018 Monday ,22 January
All set for first global medical tourism conference in DubaiGMT 22:46 2018 Sunday ,21 January
Second face transplant for FrenchmanGMT 07:51 2018 Saturday ,20 January
Trio aquitted of negligence in Canada railway disasterGMT 10:57 2018 Thursday ,18 January
Breastfeeding for 6 months cuts diabetes risk in half: studyGMT 16:10 2018 Wednesday ,17 January
Child mummy in Italy had hepatitis, not smallpoxGMT 18:36 2018 Tuesday ,16 January
Greece strikes cause transport chaos, healthcare delays

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor